- Open-label parallel-group randomized pilot trial of 60 neonates failing conventional mechanical ventilation, allocated 30 per arm to HFOV with volume guarantee or manual tidal volume monitoring.
- Compared automated volume guarantee (HFOV-VG) against careful manual monitoring of high-frequency tidal volume (HFOV-VM) as the rescue ventilation mode.
- Hypo- or hypercarbia at 1 hour occurred in 50% (15/30) with volume guarantee versus 43% (13/30) with manual monitoring, p = 0.61, with no difference at later time points.
- The authors concluded no difference in hypo/hypercarbia or complications between the two approaches as rescue therapy, and no differences in cerebral blood flow, cerebral oxygenation, or mortality.
Pediatric
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Secondary analysis of 3000 patients across 21 EPOCH trial centers, covering 4288 urgent ICU consultations grouped into care episodes.
- No intervention was assigned in this analysis; the exposure was whether patients received resuscitation during their first urgent ICU consultation.
- Half of last care episodes ended in urgent ICU admission (49.2%), with 0.1% in-consultation deaths; late escalation was 18% for first and second consultations.
- Among patients with a second consultation, prior resuscitation was linked to more resuscitation events (23.2% vs 3.4%, p<0.01), but late escalation difference was not significant (31.8% vs 15.6%, p=0.07).
- Single-centre randomized controlled trial of 62 adults in Xi'an, China, undergoing elective unilateral VATS, allocated 1:1 to lateral or supine VDLT intubation.
- Compared video double-lumen tube intubation in a modified lateral position with conventional supine intubation, with operators unblinded and outcome data collectors blinded.
- In-room to cut time was shorter with lateral intubation, 18.1 vs 31.1 min, mean difference -13.0 min (95% CI -14.4 to -11.6; P < 0.001).
- Malpositioning was 1/31 versus 15/31 and sore throat within 48 h was 9/31 versus 18/31, though secondary analyses were exploratory.
AI summary not available. Read the source abstract on PubMed.
- Multicentre randomised trial of 400 children aged 2 to under 7 years undergoing adenotonsillectomy at four tertiary hospitals in China.
- Children were randomised 1:1 to ventilation with a laryngeal mask airway or an endotracheal tube.
- Any perioperative respiratory adverse event occurred in 22.5% of the LMA group versus 57.5% of the ETT group (absolute risk difference -35.0 points, 95% CI -43.5 to -25.7; P<0.001).
- The authors conclude that LMA ventilation by experienced anaesthesiologists produced fewer respiratory adverse events, and neither group had serious adverse events.
- Randomized, double-blind dose-finding trial of 99 children aged 1-6 years undergoing adenotonsillectomy, with a glucose control group.
- Children received oral 10% glucose or oral esketamine at 1, 2, or 3 mg/kg, given 30 minutes before anesthesia.
- At cannulation, all esketamine doses improved sedation and analgesia (overall p < 0.001), greatest at 3 mg/kg, where median FLACC was 0.00 versus 6.00 in controls.
- The authors favored 2 mg/kg for balancing efficacy and safety, and 3 mg/kg for superior analgesia and opioid sparing (remifentanil 120 vs 240 μg, p = 0.001).
- Phase 2b randomized, double-blind, placebo-controlled dose-ranging trial in 110 participants after third molar extraction.
- Oral meloxicam formulation MR-107A-02 given at 1.25, 5, or 15 mg twice daily was compared with placebo.
- Mean SPID0-24 Emax values were 70.7, 86.7, and 94.8 across the doses, versus 52.0 for placebo; 5 and 15 mg were significant (p < .001).
- The 15 mg dose gave perceptible relief at 0.6 hours and meaningful relief at 1.5 hours, with the lowest rescue use (29.6%); authors report good tolerability.
- Double-blind, multicenter randomized trial of 370 nulliparous individuals aged 18 to 31 undergoing IUD placement at 11 Swedish outpatient clinics.
- Intrauterine instillation of 10 mL mepivacaine 20 mg/mL was compared with 10 mL sodium chloride placebo given 2 minutes before IUD placement.
- Mean pain on a 100-mm visual analog scale was 43.8 mm with mepivacaine versus 58.6 mm with placebo (mean difference 14.8 mm, 95% CI 10.0 to 19.6; P < .001).
- Tolerable pain was reported by 98.3% of mepivacaine recipients versus 91.4% of placebo recipients (relative risk 1.08, 95% CI 1.02 to 1.13; NNT 15).